GENEVA, 20 January 2020: The Wyss Center for Bio and Neuroengineering today announced the promotion of George Kouvas to Chief Technology Officer (CTO).
Kouvas joined the Wyss Center in February 2017, bringing his medical device industry expertise. Under his leadership, one of the Center’s flagship programs, EPIOS™ sub-scalp brain monitoring system, evolved from an initial idea to an investable technology to be validated in clinical settings. He is now taking on the CTO duties, responsible for the Center’s entire engineering activities and reporting to the Center’s Director Mary Tolikas. The appointment is effective immediately.
“George uniquely combines business acumen with advanced technology leadership,” Tolikas said. “His skills and experiences, together with his focus on innovation and urgency to translate it for human benefit, will help ensure the Center remains at the forefront of neuroengineering worldwide.”
In his new role, Kouvas will focus on strengthening the Center’s innovation activities by expanding into novel applications and on accelerating the translation of the Center’s technologies into clinical solutions, while leveraging the Center’s growing Swiss and international partnerships.
Prior to joining the Wyss Center, Kouvas was a Director and Technical leader of Merck’s eHealth platform in Switzerland. With over 20 years of experience in medical devices, neurotechnology, pharma, eHealth, eBusiness and R&D services, Kouvas holds a Diploma in Electrical and Computer Engineering and an MBA, from the National Technical University of Athens (NTUA).
Kouvas takes over from Claude Clement, who served as CTO from 2014 to late 2019.
